Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, ...
Eye care providers urged FDA advisers to approve SYD-101, citing myopia’s lifelong risks, compounding gaps and STAR trial ...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September ...
A new review finds that while AREDS formulations remain the only well-established nutritional therapy for retinal disease, ...
Auckland Eye hosted an event debunking common eyecare myths, covering topics like carrots and night vision, nAMD injections, vitrectomy ...
Jordana G. Fein, MD, MS, points to agent selection, payer requirements, and real-world treatment response across 3 retina ...
A 6-month interim analysis of Eylea HD demonstrated stable visual acuity, decreased central retinal thickness, increased ...
Typical eye pressure ranges from 10 to 20 millimeters of mercury (mmHg). Glaucoma is often associated with pressures above 21 mmHg, but eye damage can occur at different pressure levels for each ...
Descubre la oferta de oftalmología en Valencia de Quirónsalud: cirugía FEMTOLASIK, cataratas, córnea, retina y tratamiento del ojo seco con IPL ...
Acciones de Regeneron hoy: rentabilidad y valor bursátil de la acción. Consulte la cotización de Regeneron en bolsa (BVMF:REGN34) y su último precio: 62,27.
El Servicio de Oftalmología del Hospital Quirónsalud Valencia, dirigido por el doctor Enrique López Sánchez, aborda desde la ...
Investigaciones realizadas en distintos países analizaron la exposición prolongada a partículas contaminantes y su posible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results